The impact of new guidance on

By Erika Kunz

The FDA’s recent publication addresses quality control, sterility testing, labeling and other topics relevant to veterinary medications

Compounded drugs are widely used in veterinary medicine due to the large spectrum of therapeutic needs and the relatively small number of approved pharmaceuticals for all animal species and indications.1 Compounded drugs can provide therapy to animals when no suitable FDA-approved products are available. Additionally, the use of flavoring or a novel route of administration can increase uptake and adherence in patients, particularly in animals that are difficult to medicate.

Veterinary professionals became familiar with the FDA Center for Veterinary Medicine’s Updated Guidance for Industry (GFI) #256: Compounding Animal Drug from Bulk Drug Substances document during an education session at the 2023 Fetch dvm360® Conference in Charlotte, North Carolina, presented by Ernie Ward, DVM, CVFT, veterinary medical lead for Basepaws. “The FDA acknowledges that veterinarians need to turn to compounded medications,” said Marcy A. Bliss, CEO of Wedgewood Pharmacy, which sponsored the session.2

GFI #256 provides guidance for veterinary drug-compounding facilities that use bulk drug substances to compound drugs for animal use. The guidance, which took effect on April 1, 2023, covers various topics related to drug compounding, including quality control, sterility testing, labeling, record-keeping, and reporting adverse events.3 “What the FDA is trying to accomplish [with the updated

Compounding Animal Drugs

guidance] is to ensure that veterinarians use FDA-approved medications when it is applicable to their patient,” Bliss said.2

Three elements of GFI #256 that veterinarians need to be aware of include dynamic lists, medical rationale, and adverse event reporting. The guidance requires all compounded office stock medications for emergency use to be compounded from materials on the FDA-approved list of bulk drug substances. Although medications that are not on the approved list may still be prescribed for patients, these drugs cannot be ordered for in-office use. Furthermore, a medical rationale, in addition to a patient-specific prescription, will be required for medications compounded from active pharmaceutical ingredients not on the FDA’s list of bulk drug substances and that are considered copies of a commercially available product, specifically those of the same drug, dose, and route of administration.

The requirement to use FDA-approved medications in office-use compounded drug “could potentially delay the delivery of some medications. [Delivering medications] may be a process of waiting to call it in and prescribe it. Be aware that there’s been such an impact here,” said Ward.

Given that poor compounding practices can lead to bacterial or fungal contamination, the FDA is concerned about widespread harm if office stock medications are compounded in unsanitary conditions, according to Ward. Veterinarians are now required to report adverse events to the FDA via Form 1932a, which can be downloaded and mailed to the FDA.

Since the guidance is intended to ensure that animal drugs compounded from bulk dug substances are safe and effective, and meet the needs of patients, the FDA is seeking veterinarians’ input regarding which drugs compounded from its bulk drug substances lists are necessary for office use. Bliss and Ward urged veterinarians to take advantage of the opportunity to provide comments. “This is a collective effort,” Ward emphasized.

Let’s Talk AQHA brings American Quarter Horse industry leaders and experts together on a new platform.

The American Quarter Horse Association is launching Let’s Talk AQHA, the new podcast that will feature American Quarter Horse industry leaders and

NEW - Let’s Talk AQHA Podcast

experts to highlight the versatility of the American Quarter Horse.

Let’s Talk AQHA will release new episodes monthly. Among the topics addressed are: showing, racing, ranching, animal welfare, youth, AQHA news and more, with in-depth interviews with people from different areas of the equine industry.

“Let’s Talk AQHA is going to encompass all topics related to the American Quarter Horse,” said Patty Tiberg, AQHA Chief Marketing Officer. “This has been an amazing collaboration between our marketing, communication, publications and media production teams.”

Let’s Talk AQHA is scheduled to launch midAugust 2023.

About Let’s Talk AQHA

Let’s Talk AQHA spotlights the versatility, athleticism and legacy of the American Quarter Horse. The official podcast of the largest equine breed registry in the world, Let’s Talk AQHA brings American Quarter Horse industry leaders and experts together. With new episodes each month, the Let’s Talk AQHA podcast features a variety of segments in every episode, showcasing the diversity of America’s horsepower – the American Quarter Horse.

AQHA News and information is a service of the American Quarter Horse Association. For more news and information, follow @AQHA on Twitter, and visit www.aqha.com/news.+

By Kelley Detweiler July 16, 2023